Welcome to our dedicated page for Evolv Technologies Hldngs SEC filings (Ticker: EVLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies Holdings director Michael Ellenbogen reported both RSU vesting and a small share sale. He sold 82,913 shares of Class A common stock in an open-market transaction at a weighted average price of $5.19 per share, with individual trades ranging from $5.19 to $5.29, solely to cover withholding taxes owed on vesting RSUs.
On the prior day, he exercised and converted 66,787, 57,392 and 50,505 Restricted Stock Units into the same number of Class A shares at no cost, reflecting scheduled vesting of RSU awards. Each RSU represents one share and has no expiration, vesting in three equal annual installments beginning on March 1 of 2024, 2025 and 2026, respectively.
After these transactions, Ellenbogen directly owns 2,175,732 shares of Evolv Class A common stock and also reports indirect ownership of 151,135 shares held by the Family Horizon Trust.
Evolv Technologies Holdings founder and Chief Growth Officer Anil Chitkara reported multiple equity transactions. He received a grant of 46,728 Restricted Stock Units (RSUs) on March 2, 2026, which vest in three equal annual installments commencing on March 2, 2027.
On March 1, 2026, he exercised several RSU awards, converting 53,430, 45,913 and 37,878 RSUs into an equal number of Class A common shares at no cost. He then sold 63,670 Class A shares at a weighted average price of $5.19 per share, in transactions ranging from $5.19 to $5.30.
According to the disclosure, this sale was effected solely to cover withholding taxes related to RSU vesting. After the transactions, he directly owned 1,348,651 Class A common shares and continued to hold additional unvested RSUs subject to multi-year vesting schedules.
Evolv Technologies Holdings, Inc. reported that director Henrik Kuhl acquired 9,291 restricted stock units (RSUs) as a grant. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.
The RSUs will vest in full at the earlier of June 20, 2026 or the day immediately before the company’s next annual meeting. Following this grant, Kuhl holds a total of 9,291 RSUs directly.
Evolv Technologies Holdings, Inc. director Henrik Kuhl filed an initial insider ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider, but it does not report any share purchases, sales, or other transactions.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen exercised a stock option for 80,745 shares on February 17, 2026, converting options at an exercise price of $0.24 per share into Class A common stock. The same day, he sold 80,745 Class A shares in an open-market transaction at a weighted average price of $5.47 per share, with individual trades ranging from $5.39 to $5.65, under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025. Following these transactions, he directly owned 2,083,961 Class A shares and indirectly held 151,135 shares through Family Horizon Trust.
Evolv Technologies Holdings, Inc. announced a Board change, with long-time director and early venture investor Bilal Zuberi resigning to pursue other endeavors, with no disagreements cited with leadership or the Board.
The company appointed Henrik Kühl, age 46, to its Board of Directors effective February 12, 2026, as a Class III director through the 2027 annual meeting. He will also serve on the Audit Committee. The Board determined that Kühl is independent under Nasdaq and SEC rules and qualifies as an “audit committee financial expert.”
Kühl brings more than 25 years of experience in corporate strategy and development, including his current role as Senior Vice President, Strategy & Corporate Development at Axon. He will receive compensation as a non-employee director under Evolv’s Director Compensation Policy.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported option exercises and share sales in Class A Common Stock. On January 16, 2026, he exercised a stock option for 80,745 shares at an exercise price of $0.24 per share and acquired the same number of shares. That same day, he sold 80,745 shares at a weighted average price of $6.20 per share, with individual sale prices ranging from $6.13 to $6.37, under a pre-existing Rule 10b5-1 trading plan entered into on June 12, 2025.
After these transactions, Ellenbogen directly beneficially owned 2,083,961 shares of Class A Common Stock and held 1,300,739 stock options. He also indirectly held 151,135 shares through the Family Horizon Trust.
Evolv Technologies Holdings, Inc. reported that director Mark J. Sullivan received a grant of 3,731 Restricted Stock Units (RSUs) on January 2, 2026. Each RSU represents a contingent right to receive one share of the company’s Class A common stock at no purchase price, and the RSUs have no expiration date.
The filing states that these 3,731 RSUs will vest in full on December 31, 2026, after which they can settle into an equal number of Class A common shares, assuming vesting conditions are met. Following this award, Sullivan beneficially owns 3,731 RSUs directly.
Evolv Technologies Holdings, Inc. (EVLV) reported a new equity grant to one of its directors. Director Michael Ellenbogen was awarded 3,731 Restricted Stock Units (RSUs) on January 2, 2026, at a price of $0 per unit, and now holds 3,731 derivative securities directly following this transaction.
Each RSU represents a contingent right to receive one share of Evolv’s Class A common stock and has no expiration date. According to the disclosure, all 3,731 RSUs will vest in full on December 31, 2026, meaning Ellenbogen will receive an equal number of Class A shares if the vesting conditions are satisfied.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported insider transactions in Class A Common Stock. On December 15, 2025 he exercised stock options for 80,745 shares at an exercise price of $0.24 per share and on the same day sold 80,745 shares at a weighted average price of $6.91 per share under a Rule 10b5-1 trading plan entered into on June 12, 2025. The sales occurred in multiple trades at prices ranging from $6.75 to $7.20.
After these transactions he held 2,083,961 shares directly, 151,135 shares indirectly through the Family Horizon Trust, and 1,381,484 stock options.